Market Overview

UPDATE: Credit Suisse Lowers PT on Arena Pharmaceuticals Following Management Meeting

Related ARNA
33 Biggest Movers From Yesterday
Mid-Afternoon Market Update: MuleSoft Gains Following Report Of Takeover Interest From Salesforce; Proteostasis Therapeutics Shares Slide
Arena Raises Impressive $352 Million On Stock Offering (Seeking Alpha)

In a report published Monday, Credit Suisse analyst Lee Kalowski reiterated an Underperform rating on Arena Pharmaceuticals (NASDAQ: ARNA), but lowered the price target from $5.00 to $4.00.

In the report, Credit Suisse noted, “As Q3 closes and following a Friday meeting with management, we are lowering our Belviq US net sales estimate for Q3, Q4, and each year through 2018 (2019-2020 are unchanged). We expect consensus will be coming down in the weeks ahead. We think a capital raise may potentially be required next year and have built this into our model. With these changes, our DCF-derived target price goes from $5 to $4.”

Arena Pharmaceuticals closed on Friday at $5.79.

Latest Ratings for ARNA

Mar 2018NeedhamUpgradesHoldBuy
Feb 2018CitigroupMaintainsBuyBuy
Jan 2018Credit SuisseInitiates Coverage OnOutperform

View More Analyst Ratings for ARNA
View the Latest Analyst Ratings

Posted-In: Credit Suisse Lee KalowskiAnalyst Color Price Target Analyst Ratings


Related Articles (ARNA)

View Comments and Join the Discussion!